

# Silvana Galderisi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3157976/publications.pdf>

Version: 2024-02-01

230  
papers

12,738  
citations

28190  
55  
h-index

30010  
103  
g-index

256  
all docs

256  
docs citations

256  
times ranked

12027  
citing authors

#	ARTICLE	IF	CITATIONS
1	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMISE study. <i>Psychological Medicine</i> , 2023, 53, 3471-3479.	2.7	6
2	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	1.3	4
3	A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 238-251.	1.0	28
4	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	1.3	13
5	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 193-203.	1.1	4
6	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 161-170.	1.1	5
7	Negative Symptom Domains in Children and Adolescents at Ultra-High Risk for Psychosis: Association With Real-Life Functioning. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	4
8	We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. <i>Schizophrenia Research</i> , 2022, 242, 30-34.	1.1	9
9	Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). <i>Frontiers in Psychiatry</i> , 2022, 13, 833550.	1.3	2
10	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 61.	1.0	10
11	Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	2.2	4
12	Neglected Vulnerabilities in Mental Health: Where Do We Need to Do More?. , 2022, , 335-369.		1
13	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMISE trial. <i>European Psychiatry</i> , 2022, 65, .	0.1	4
14	Determinants of Clinical Recovery in Schizophrenia. <i>Comprehensive Approach To Psychiatry</i> , 2022, , 23-43.	0.7	1
15	Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 541-555.	1.4	15
16	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. <i>Journal of Psychiatric Research</i> , 2021, 133, 38-45.	1.5	12
17	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMISE Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 444-455.	2.3	9
18	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.1	15

#	ARTICLE	IF	CITATIONS
19	EPA guidance on treatment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e21.	0.1	70
20	Autism Rating Scale: A New Tool for Characterizing the Schizophrenia Phenotype. <i>Frontiers in Psychiatry</i> , 2021, 12, 622359.	1.3	7
21	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 29-35.	1.1	11
22	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 11.	2.0	18
23	P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 44, S44-S45.	0.3	0
24	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	6.0	89
25	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110250.	2.5	18
26	ITALian Partnership for Psychosis Prevention (ITAPP): improving the mental health of young people. <i>European Psychiatry</i> , 2021, 64, 1-21.	0.1	4
27	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021, 294, 957-970.	2.0	23
28	The clinical characterization of the patient with primary psychosis aimed at personalization of management. <i>World Psychiatry</i> , 2021, 20, 4-33.	4.8	153
29	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.1	94
30	Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG). <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 82-89.	1.2	6
31	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. <i>European Psychiatry</i> , 2021, 64, e71.	0.1	20
32	Tracing Links Between Early Auditory Information Processing and Negative Symptoms in Schizophrenia: An ERP Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 790745.	1.3	9
33	P.0589 Resting-state functional connectivity of the ventral tegmental area and negative symptoms in subjects with schizophrenia: a resting-state functional MRI study. <i>European Neuropsychopharmacology</i> , 2021, 53, S431-S432.	0.3	0
34	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. <i>Brain Sciences</i> , 2021, 11, 1632.	1.1	12
35	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. <i>Journal of Clinical Medicine</i> , 2021, 10, 5838.	1.0	8
36	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 789179.	1.3	35

#	ARTICLE	IF	CITATIONS
37	P.0592 Investigating the relationships of N100-P3b with symptom dimensions and cognitive impairments in subjects with chronic schizophrenia. <i>European Neuropsychopharmacology</i> , 2021, 53, S432-S433.	0.3	0
38	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. <i>Frontiers in Psychiatry</i> , 2021, 12, 791117.	1.3	15
39	Questionnaire on Attitude towards Research and Care (QuARC): a survey of patients with psychosis. <i>Journal of Mental Health</i> , 2020, 29, 590-596.	1.0	0
40	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studiesâ€”PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	2.3	56
41	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	4.8	96
42	How mental health care should change as a consequence of the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 813-824.	3.7	1,101
43	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. <i>European Psychiatry</i> , 2020, 63, 1-21.	0.1	30
44	P.778 Electrophysiological indices and expressive deficit domain of negative symptoms in subjects with schizophrenia. <i>European Neuropsychopharmacology</i> , 2020, 40, S442.	0.3	0
45	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. <i>European Psychiatry</i> , 2020, 63, e98.	0.1	20
46	â€Precision psychiatryâ€™ needs to become part of â€personalized psychiatryâ€™. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2020, 88, 767-772.	0.3	6
47	Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features. <i>European Psychiatry</i> , 2020, 63, e49.	0.1	5
48	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia â€“ data from the OPTiMiSE trial. <i>Psychiatry Research</i> , 2020, 289, 112970.	1.7	11
49	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. <i>Frontiers in Neuroscience</i> , 2020, 14, 632.	1.4	17
50	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	6.0	287
51	Schizophrenia and â€unmet needsâ€ From diagnosis to care in Italy. <i>European Psychiatry</i> , 2020, 63, e26.	0.1	9
52	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020, 34, 76-86.	0.3	30
53	Transitions in mental health care: The European Psychiatric Association contribution to reform in Bulgaria. <i>European Psychiatry</i> , 2020, 63, 1-13.	0.1	20
54	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.3	60

#	ARTICLE	IF	CITATIONS
55	Beyond the Transnosographic Emphasis on Psychosis: Nosological Perspectives on Schizophrenia and Its Prevention. <i>Frontiers in Psychiatry</i> , 2019, 10, 666.	1.3	8
56	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.3	38
57	The UN Convention on the Rights of Persons with Disabilities: great opportunities and dangerous interpretations. <i>World Psychiatry</i> , 2019, 18, 47-48.	4.8	5
58	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
59	White matter structural connectivity abnormalities in subjects with deficit schizophrenia: A diffusion tensor imaging study. <i>European Neuropsychopharmacology</i> , 2019, 29, S110.	0.3	0
60	Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives. <i>European Neuropsychopharmacology</i> , 2019, 29, S336.	0.3	0
61	Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings. <i>International Journal of Psychophysiology</i> , 2019, 145, 99-108.	0.5	23
62	Toward Clinical Translation of Neuroimaging Research in Schizophrenia and Other Primary Psychotic Disorders. , 2019, , 327-345.		1
63	The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. <i>Schizophrenia Research</i> , 2019, 208, 235-241.	1.1	22
64	The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. <i>European Psychiatry</i> , 2019, 58, 1-9.	0.1	75
65	&lt;p&gt;The Efficacy, Feasibility And Acceptability Of A Remotely Accessible Use Of CIRCuITS, A Computerized Cognitive Remediation Therapy Program For Schizophrenia: A Pilot Study&lt;p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3103-3113.	1.0	6
66	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 1033-1041.	2.3	88
67	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 126-136.	1.3	12
68	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 305-314.	2.3	99
69	Neuroimaging: Diagnostic Boundaries and Biomarkers. , 2019, , 1-56.		1
70	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. <i>European Neuropsychopharmacology</i> , 2018, 28, 589-602.	0.3	32
71	Current trends in diagnosis and treatment of mental disorders. <i>European Psychiatry</i> , 2018, 50, 4-6.	0.1	3
72	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	6.0	214

#	ARTICLE	IF	CITATIONS
73	Negative symptoms of schizophrenia: new developments and unanswered research questions. <i>Lancet Psychiatry</i> , 2018, 5, 664-677.	3.7	316
74	The complex relationship between self-reported "personal recovery" and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 108-112.	1.1	45
75	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	2.7	37
76	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 55-65.	0.9	31
77	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 46-54.	0.9	8
78	Acute Effects of Music Therapy in Subjects With Psychosis During Inpatient Treatment. <i>Psychiatry (New York)</i> , 2018, 81, 218-227.	0.3	16
79	Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study. <i>NeuroImage: Clinical</i> , 2018, 20, 627-636.	1.4	39
80	Untangling the Factors Contributing to Functional Outcome in Schizophrenia—Reply. <i>JAMA Psychiatry</i> , 2018, 75, 754.	6.0	4
81	United Nations convention on the rights of persons with disabilities needs to be interpreted on the basis of scientific evidence regarding psychiatry. <i>European Psychiatry</i> , 2018, 51, 87-89.	0.1	166
82	Value of schizophrenia treatment I: The patient journey. <i>European Psychiatry</i> , 2018, 53, 107-115.	0.1	28
83	Value of schizophrenia treatment II: Decision modelling for developing early detection and early intervention services in the Czech Republic. <i>European Psychiatry</i> , 2018, 53, 116-122.	0.1	9
84	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 253-266.	2.2	44
85	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	3.7	141
86	Future coordination and integration of the results of the EU funded projects on schizophrenia and other mental disorders. <i>European Psychiatry</i> , 2018, 50, 1-3.	0.1	0
87	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. <i>Schizophrenia Research</i> , 2018, 201, 105-112.	1.1	52
88	Psychiatry and psychiatrists: Fourteen core statements. <i>European Psychiatry</i> , 2018, 52, 136-138.	0.1	1
89	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. <i>Schizophrenia Research</i> , 2017, 186, 19-28.	1.1	110
90	Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. <i>Schizophrenia Research</i> , 2017, 186, 1-2.	1.1	31

#	ARTICLE	IF	CITATIONS
91	Editorial: The EPA, Brexit and beyond. <i>European Psychiatry</i> , 2017, 42, 27-28.	0.1	0
92	The current conceptualization of negative symptoms in schizophrenia. <i>World Psychiatry</i> , 2017, 16, 14-24.	4.8	354
93	Primary, Enduring Negative Symptoms: An Update on Research. <i>Schizophrenia Bulletin</i> , 2017, 43, 730-736.	2.3	85
94	Categorizing and assessing negative symptoms. <i>Current Opinion in Psychiatry</i> , 2017, 30, 201-208.	3.1	30
95	EPA position paper: Improving the image of psychiatry and psychiatrists. <i>European Psychiatry</i> , 2017, 42, 24-26.	0.1	1
96	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. <i>European Psychiatry</i> , 2017, 40, 65-75.	0.1	241
97	Effects of chronic antipsychotic treatment on neurophysiological correlates of the auditory oddball task in schizophrenia: A preliminary report from a multicentre study. <i>European Psychiatry</i> , 2017, 41, S192-S192.	0.1	0
98	Functional connectivity of the ventral tegmental area and avolition in schizophrenia: A resting state functional MRI study. <i>European Psychiatry</i> , 2017, 41, S196-S196.	0.1	0
99	Electrophysiological Correlates of Negative Symptom Domains in Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S96-S97.	0.1	0
100	Disorganization in Schizophrenia: A Resting EEG Study. <i>European Psychiatry</i> , 2017, 41, S100-S100.	0.1	0
101	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017, 256, 359-364.	1.7	49
102	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 285-294.	1.8	33
103	Resilience in people with schizophrenia. Results from the Italian Network for Research on Psychoses. <i>European Journal of Public Health</i> , 2017, 27, .	0.1	1
104	SoCIAL &ndash; training cognition in schizophrenia: a pilot study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1947-1956.	1.0	12
105	A proposed new definition of mental health. <i>Psychiatria Polska</i> , 2017, 51, 407-411.	0.2	29
106	Negative symptoms domains: pathways to functional outcome in schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, S123.	0.3	0
107	Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, S506-S507.	0.3	1
108	Electrophysiological mechanisms underlying ERP amplitude reduction in patients with schizophrenia: A time-frequency analysis. <i>European Psychiatry</i> , 2016, 33, S104-S104.	0.1	0

#	ARTICLE	IF	CITATIONS
109	The social cognition individualized activities lab: Implementation of a new remediation intervention for social cognition. <i>European Psychiatry</i> , 2016, 33, S567-S567.	0.1	0
110	The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. <i>Schizophrenia Bulletin</i> , 2016, 42, 1225-1233.	2.3	61
111	A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia. <i>European Psychiatry</i> , 2016, 33, S574-S574.	0.1	0
112	Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. <i>BMJ, The</i> , 2016, 354, i4728.	3.0	4
113	Relationships between neurocognition, social cognition and functional outcome in schizophrenia. <i>European Psychiatry</i> , 2016, 33, S67-S67.	0.1	1
114	Social cognition in people with schizophrenia: a cluster-analytic approach. <i>Psychological Medicine</i> , 2016, 46, 2717-2729.	2.7	65
115	Shall we really say goodbye to first rank symptoms?. <i>European Psychiatry</i> , 2016, 37, 8-13.	0.1	30
116	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. <i>Schizophrenia Research</i> , 2016, 175, 154-160.	1.1	66
117	Relation between EEG source functional connectivity and the negative symptom severity in schizophrenia: a preliminary report from a multicentre study. <i>European Psychiatry</i> , 2016, 33, s246-s246.	0.1	0
118	The second-generation assessment scales: Brief negative symptom scale and clinical assessment interview for negative symptoms. <i>European Psychiatry</i> , 2016, 33, S70-S70.	0.1	2
119	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. <i>Clinical Neurophysiology</i> , 2016, 127, 2149-2160.	0.7	45
120	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. <i>Schizophrenia Research</i> , 2016, 174, 172-176.	1.1	25
121	Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. <i>Psychological Medicine</i> , 2015, 45, 1765-1778.	2.7	108
122	Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 361-366.	1.3	50
123	Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. <i>Schizophrenia Bulletin</i> , 2015, 41, 574-583.	2.3	94
124	Neurobiological background of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 543-558.	1.8	81
125	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. <i>European Psychiatry</i> , 2015, 30, 641-647.	0.1	114
126	Toward a new definition of mental health. <i>World Psychiatry</i> , 2015, 14, 231-233.	4.8	383



#	ARTICLE	IF	CITATIONS
127	Facial emotion recognition impairment is related to disorganisation in multi-episode schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 122-125.	0.7	2
128	Schizophrenia–Time to Commit to Policy Change. <i>Schizophrenia Bulletin</i> , 2014, 40, S165-S194.	2.3	153
129	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	4.8	346
130	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. <i>Schizophrenia Research</i> , 2014, 159, 144-150.	1.1	64
131	Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 129-156.	0.8	32
132	Physiological Correlates of Positive Symptoms in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 21, 103-128.	0.8	13
133	Transcranial Direct Current Stimulation for Autistic Disorder. <i>Biological Psychiatry</i> , 2014, 76, e5-e6.	0.7	31
134	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 69-75.	1.1	24
135	Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. <i>Schizophrenia Research</i> , 2013, 147, 157-162.	1.1	148
136	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 196-204.	0.3	137
137	Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. <i>Schizophrenia Research</i> , 2013, 147, 132-139.	1.1	48
138	Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-1 gene (PPARA) and schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 749-759.	0.3	26
139	Impulsiveness in Patients with Bulimia Nervosa: Electrophysiological Evidence of Reduced Inhibitory Control. <i>Neuropsychobiology</i> , 2013, 68, 116-123.	0.9	8
140	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. <i>Psychological Medicine</i> , 2012, 42, 1461-1473.	2.7	26
141	No gender differences in social outcome in patients suffering from schizophrenia. <i>European Psychiatry</i> , 2012, 27, 406-408.	0.1	53
142	A functional comparison of patients with schizophrenia between the North and South of Europe. <i>European Psychiatry</i> , 2012, 27, 442-444.	0.1	7
143	Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study. <i>Laterality</i> , 2012, 17, 217-224.	0.5	6
144	Dorsolateral prefrontal cortex volume in patients with deficit or nondéficit schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 264-269.	2.5	30

#	ARTICLE	IF	CITATIONS
145	The interrelation of needs and quality of life in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 207-216.	1.8	15
146	CS06-03 - Relationship between cognition and psychopathology. <i>European Psychiatry</i> , 2011, 26, 1788-1788.	0.1	0
147	Effects of antipsychotics on cognitive functions: an ERP study in healthy controls. <i>European Psychiatry</i> , 2011, 26, 1267-1267.	0.1	1
148	Which Outcome Indices Would Clinicians Like to See in Schizophrenia Clinical Trials?. <i>European Psychiatry</i> , 2011, 26, 2204-2204.	0.1	0
149	Primary and enduring negative symptoms in first episode and chronic patients with schizophrenia. <i>European Psychiatry</i> , 2011, 26, 2068-2068.	0.1	0
150	Perception of body shape in bulimia nervosa: An ERP study. <i>European Psychiatry</i> , 2011, 26, 741-741.	0.1	0
151	Physiologic Basis of the EEG Signal. , 2011, , 7-12.		4
152	EEG in Delirium and Dementia. , 2011, , 147-162.		1
153	Standard EEG in Personality and Anxiety Disorders. , 2011, , 133-146.		1
154	Social skills vs. Neurocognitive training in psychotic patients. <i>European Psychiatry</i> , 2011, 26, 1475-1475.	0.1	1
155	Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 159-165.	1.6	15
156	Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. <i>Psychological Medicine</i> , 2011, 41, 839-848.	2.7	26
157	Frequency and clinical correlates of adult separation anxiety in a sample of 508 outpatients with mood and anxiety disorders. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 40-46.	2.2	73
158	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 305-315.	1.8	47
159	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. <i>Psychiatry Research</i> , 2010, 176, 82-84.	1.7	24
160	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). <i>American Journal of Psychiatry</i> , 2009, 166, 675-682.	4.0	284
161	Evidence-Based Medicine and Electrophysiology in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2009, 40, 62-77.	0.9	85
162	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. <i>Psychoneuroendocrinology</i> , 2009, 34, 1506-1514.	1.3	221

#	ARTICLE	IF	CITATIONS
163	Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST). <i>Schizophrenia Research</i> , 2009, 115, 97-103.	1.1	107
164	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. <i>Schizophrenia Research</i> , 2009, 115, 104-114.	1.1	102
165	Deficit schizophrenia: An overview of clinical, biological and treatment aspects. <i>European Psychiatry</i> , 2009, 24, 493-500.	0.1	84
166	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. <i>Psychiatric Genetics</i> , 2009, 19, 110-111.	0.6	56
167	Cerebral connectivity and psychotic personality traits. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 292-299.	1.8	23
168	Alexithymia and Cognitive Dysfunctions in Patients with Panic Disorder. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 182-188.	4.0	66
169	The status of spectral EEG abnormality as a diagnostic test for schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 225-237.	1.1	255
170	DEFICIT SCHIZOPHRENIA: A VALID CATEGORICAL SUBTYPE OF SCHIZOPHRENIA?. <i>Schizophrenia Research</i> , 2008, 102, 45.	1.1	1
171	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet, The</i> , 2008, 371, 1085-1097.	6.3	964
172	The added value of including cognitive impairment in the diagnostic criteria for schizophrenia. <i>World Psychiatry</i> , 2008, 7, 36-37.	4.8	3
173	Deficit schizophrenia: an update. <i>World Psychiatry</i> , 2008, 7, 143-147.	4.8	171
174	Cognitive-enhancing effects of aripiprazole: a case report. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2008, 4, 24.	0.6	12
175	Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 393-401.	2.3	85
176	Induced Gamma Activity and Event-Related Coherence in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2007, 38, 96-104.	0.9	57
177	The cortical generators of P3a and P3b: A LORETA study. <i>Brain Research Bulletin</i> , 2007, 73, 220-230.	1.4	210
178	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2007, 92, 252-261.	1.1	57
179	Neurocognitive indices of executive hypercontrol in obsessive-compulsive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 380-387.	2.2	34
180	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. <i>Human Brain Mapping</i> , 2006, 27, 162-172.	1.9	253

#	ARTICLE	IF	CITATIONS
181	Motion standstill leads to activation of inferior parietal lobe. <i>Human Brain Mapping</i> , 2006, 27, 340-349.	1.9	5
182	Pharmaco-EEG: A History of Progress and a Missed Opportunity. <i>Clinical EEG and Neuroscience</i> , 2006, 37, 61-65.	0.9	21
183	Pharmaco-EEG in Psychiatry. <i>Clinical EEG and Neuroscience</i> , 2006, 37, 81-98.	0.9	59
184	Hemispheric lateralization patterns and psychotic experiences in healthy subjects. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 141-154.	0.9	16
185	EEG microstate duration and syntax in acute, medication-naïve, first-episode schizophrenia: a multi-center study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 138, 141-156.	0.9	316
186	Catechol-O-Methyltransferase Val <sup>158</sup> Met Polymorphism in Schizophrenia: Associations with Cognitive and Motor Impairment. <i>Neuropsychobiology</i> , 2005, 52, 83-89.	0.9	51
187	Modified nutritional counselling to increase motivation to treatment in anorexia nervosa. <i>European Psychiatry</i> , 2005, 20, 186-187.	0.1	48
188	Decrease of functional coupling between left and right auditory cortices during dichotic listening: An electroencephalography study. <i>Neuroscience</i> , 2005, 136, 323-332.	1.1	21
189	COMT Val158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. <i>Schizophrenia Research</i> , 2005, 73, 27-30.	1.1	42
190	Selected E-INSR 2004 Conference Presentation Abstracts. <i>Journal of Neurotherapy</i> , 2005, 9, 103-108.	0.9	0
191	Inhibition of auditory cortical responses to ipsilateral stimuli during dichotic listening: evidence from magnetoencephalography. <i>European Journal of Neuroscience</i> , 2004, 19, 2329-2336.	1.2	90
192	Executive hypercontrol in obsessive-compulsive disorder: electrophysiological and neuropsychological indices. <i>Clinical Neurophysiology</i> , 2004, 115, 1340-1348.	0.7	60
193	Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. <i>Biological Psychiatry</i> , 2003, 53, 921-927.	0.7	50
194	Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study. <i>American Journal of Psychiatry</i> , 2002, 159, 983-990.	4.0	127
195	Stereotaxy-Based Regional Brain Volumetry Applied to Segmented MRI: Validation and Results in Deficit and Nondeficit Schizophrenia. <i>NeuroImage</i> , 2002, 17, 373-384.	2.1	49
196	Psychophysiology in psychiatry: new perspectives in the study of mental disorders. <i>World Psychiatry</i> , 2002, 1, 166-8.	4.8	4
197	Clinical applications of pharmaco-EEG in psychiatry: the prediction of response to treatment with antipsychotics. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2002, 24 Suppl C, 85-9.	0.8	3
198	Predicting response to antipsychotics by electrophysiological indices. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2002, 24 Suppl D, 79.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Brain electrical microstates in subjects with panic disorder. <i>Brain Research Bulletin</i> , 2001, 54, 427-435.	1.4	15
200	Brain Hemispheric Organization, Anxiety, and Psychoses. <i>CNS Spectrums</i> , 2000, 5, 58-69.	0.7	76
201	Emotions, Brain Development, and Psychopathologic Vulnerability. <i>CNS Spectrums</i> , 2000, 5, 44-48.	0.7	13
202	Qualitative MRI findings in patients with schizophrenia: a controlled study. <i>Psychiatry Research - Neuroimaging</i> , 2000, 98, 117-126.	0.9	19
203	S21.02 Cognitive dysfunctions in psychotic patients: Relationship with symptoms and antipsychotic treatment. <i>European Psychiatry</i> , 2000, 15, 252s-252s.	0.1	0
204	â€Simple schizophreniaâ€™: a controlled MRI and clinical/neuropsychological study. <i>Psychiatry Research - Neuroimaging</i> , 1999, 91, 175-184.	0.9	16
205	Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. <i>International Journal of Psychophysiology</i> , 1999, 34, 293-301.	0.5	38
206	EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics. <i>European Psychiatry</i> , 1998, 13, 197S-197S.	0.1	0
207	Quantitative EEG in Psychiatry: From Research to Clinical Applications. <i>European Psychiatry</i> , 1997, 12, 105s-105s.	0.1	0
208	Quantitative EEG reactivity to neuroleptic challenge in first-episode and chronic schizophrenics. <i>Biological Psychiatry</i> , 1997, 42, 64S.	0.7	1
209	Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. <i>Psychiatry Research - Neuroimaging</i> , 1996, 67, 113-122.	0.9	24
210	Neuropsychological Slowness in Obsessiveâ€Compulsive Patients. <i>British Journal of Psychiatry</i> , 1995, 167, 394-398.	1.7	78
211	Correspondence. <i>Schizophrenia Research</i> , 1995, 14, 265-266.	1.1	6
212	QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. <i>Biological Psychiatry</i> , 1994, 35, 367-374.	0.7	50
213	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-135.	0.3	72
214	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-135.	0.3	201
215	Haloperidol-Induced Changes of Computerized Electroencephalogram Topography in Drug-Free Schizophrenic Patients. , 1993, , 245-250.		0
216	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. <i>Archives of Clinical Neuropsychology</i> , 1993, 8, 123-35.	0.3	79

#	ARTICLE	IF	CITATIONS
217	Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. <i>International Journal of Psychophysiology</i> , 1992, 13, 283-290.	0.5	35
218	Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. <i>International Journal of Psychophysiology</i> , 1991, 10, 225-230.	0.5	13
219	CEEG mapping in drug-free schizophrenics. <i>Schizophrenia Research</i> , 1991, 6, 15-23.	1.1	56
220	C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment. <i>European Neuropsychopharmacology</i> , 1990, 1, 51-54.	0.3	15
221	Factors associated with increased noradrenaline levels in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1990, 14, 49-59.	2.5	18
222	Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study. <i>Biological Psychiatry</i> , 1989, 26, 756-759.	0.7	78
223	Lateralization patterns of verbal stimuli processing assessed by reaction time and event-related potentials in schizophrenic patients. <i>International Journal of Psychophysiology</i> , 1988, 6, 167-176.	0.5	19
224	Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. <i>Psychiatry Research</i> , 1987, 21, 137-149.	1.7	58
225	Factors associated with decreased platelet MAO activity in chronic schizophrenics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1987, 11, 79-86.	2.5	5
226	Conditional Associative Learning in Drug-Free Schizophrenic Patients. <i>Neuropsychobiology</i> , 1987, 17, 30-34.	0.9	27
227	Relationship between CSF noradrenaline levels, C&#x2013;EEG indicators of activation and psychosis ratings in drug&#x2013;free schizophrenic patients. <i>Acta Psychiatrica Scandinavica</i> , 1985, 71, 19-24.	2.2	31
228	Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia. <i>Journal of Psychiatric Research</i> , 1985, 19, 587-596.	1.5	51
229	Psychophysiology of Mood Disorders. , 0, , 777-790.		0
230	Neurophysiological Research in Psychiatry. , 0, , 125-180.		1